Date
...
Stakeholder group | SHIELD organization | Name of SHIELD member | organization designation |
Industry Entity | Labgnostic, Inc. | Steve Box | primary |
| NEW: Scott Vardy | alternate | |
Epic | Dan Rutz | primary | |
|
| alternate | |
Biomerieux | Xavier Gansel | primary | |
|
| alternate | |
Roche | Nick Decker - regrets | primary | |
Roche | Yue Jin | alternate | |
Healthcare Provider | Indiana University/Indiana University Health/Association for Molecular Pathology | Mehdi Nassiri, MD | primary |
University of Wisconsin-Madison | Andrea Pitkus, PhD, MLS(ASCP)CM, FAMIA | primary | |
UT Southwestern Medical Center | Hung Luu | primary | |
UNMC | Scott Campbell | primary | |
Tufts Medical Center | Nanguneri Nirmala | primary | |
Sonic Healthcare | Eric Crugnale | primary | |
Former Quest Diagnostics | Collom, Craig D | primary | |
Patient Advocate |
| Stacy Lange | individual |
Standards Organization | SNOMED International
| Jim Case | primary |
Monica Harry - regrets | alternate | ||
Regenstrief Institute
| Marjorie Rallins | primary | |
Eza Hafeza | alternate | ||
HL7
| Julia Skapik - regrets | primary | |
| alternate | ||
Professional Organization | Association of Public Health Laboratories
| Riki Merrick | primary |
NEW: Christina Gallegos | alternate | ||
Graphite Health
| Stan Huff - regrets | primary | |
| alternate | ||
CAP
| Raj Dash - regrets | primary | |
| alternate | ||
AMP
| Robyn Temple | primary | |
| alternate | ||
Governmental - non Voting | CMS | Michael Smalara | primary |
Open | alternate | ||
ONC | Sara Armson | primary | |
| alternate | ||
CDC | Hubert Vesper (/DDNID/NCEH/DLS) | primary | |
| alternate | ||
NLM - regrets | John Snyder | primary | |
| alternate | ||
FDA | Keith Campbell - regrets | primary | |
Victoria Victoria Derbyshire - regrets | alternate |
Agenda and Notes
Item | Notes | ||||
---|---|---|---|---|---|
Quorum evaluation (two-thirds (2/3) of the Voting Representatives shall be necessary to constitute a quorum for the transaction of business) | Currently we have 19 named members, so 2/3 = 12 (excluding chair and government members).
| ||||
Open Meeting | 12:0? 10 PM ET, no quorum reached | ||||
Reminder of open action items / outcome of action items |
| ||||
Collaborative Community Panel Presentation December 17, 2024 3:50 - 4:20 P | Review proposed answers to the questions | ||||
Content for Collaborative Community website | Received content request from FDA for Collaborative Community website - what do we want to highlight there?: https://www.fda.gov/about-fda/cdrh-strategic-priorities-and-updates/collaborative-communities-addressing-health-care-challenges-together Ideas to highlight:
| ||||
Conferences | ASCLS got submitted - waiting for response
ADLM got submitted - waiting for response | ||||
Other presentations to folks at FDA? |
| ||||
Review Working Groups progress | THANK YOU to all the WG Chairs for their effort in moving SHIELD work forward!!! Setting milestones for deliverables should be NEXT for WGs: they will be captured here: SHIELD WG Deliverables and Milestone Grid
| ||||
Administrative things | Review SC Composition, terms and requirements for re-voting:
| ||||
Roadmap section updates in response to ONC comments on the SHIELD roadmap |
Updated language draft:Roadmap update: ONC Feedback maybe add one more sentence or add a reference to the key consideration number for the IVD Datahub (Consideration 4) into these sentences. (change approved in principle.) Discussion:
Update from Standards and Vocab WG about re-write of this section - from their March 18th call (notes here, recording here)
Discussion:
Identify components that could improve the ecosystem infrastructure, and then highlight the places where these components can be advanced / sustained or made easier to implement. Would SHIELD be willing to consider to provide an example implementation - create the structures and bound terminologies to showcase how each element would be properly represented be working. For each of the Consideration sections we could certainly add a section on feasibility / requirements (e.g. continued funding for LIDR, better describing the intended use of ANY data element added, overall goal of LIDR, clearly delineate what is commonly used and is minimum, provide best practice and alternatives (non-preferred) - example would be metadata around the value sets in VSAC (curation / usage etc) to be able to ascertain quality) and highlight that other mechanisms are needed to achieve for adoption. | ||||
Antimicrobial result reporting | Placeholder to get back to later Related work at HL7 Europe:
| ||||
Next calls | All SHIELD Calls
General Updates: 2024 - WG Chairs please make sure we have material for updates (at least notes we can link to) Special Topic:
Steering Committee:
| ||||
Adjourned | 12: PM ET |
...